» Articles » PMID: 27092497

The Development of Sugar-Based Anti-Melanogenic Agents

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2016 Apr 20
PMID 27092497
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The regulation of melanin production is important for managing skin darkness and hyperpigmentary disorders. Numerous anti-melanogenic agents that target tyrosinase activity/stability, melanosome maturation/transfer, or melanogenesis-related signaling pathways have been developed. As a rate-limiting enzyme in melanogenesis, tyrosinase has been the most attractive target, but tyrosinase-targeted treatments still pose serious potential risks, indicating the necessity of developing lower-risk anti-melanogenic agents. Sugars are ubiquitous natural compounds found in humans and other organisms. Here, we review the recent advances in research on the roles of sugars and sugar-related agents in melanogenesis and in the development of sugar-based anti-melanogenic agents. The proposed mechanisms of action of these agents include: (a) (natural sugars) disturbing proper melanosome maturation by inducing osmotic stress and inhibiting the PI3 kinase pathway and (b) (sugar derivatives) inhibiting tyrosinase maturation by blocking N-glycosylation. Finally, we propose an alternative strategy for developing anti-melanogenic sugars that theoretically reduce melanosomal pH by inhibiting a sucrose transporter and reduce tyrosinase activity by inhibiting copper incorporation into an active site. These studies provide evidence of the utility of sugar-based anti-melanogenic agents in managing skin darkness and curing pigmentary disorders and suggest a future direction for the development of physiologically favorable anti-melanogenic agents.

Citing Articles

Rifampicin Repurposing Reveals Anti-Melanogenic Activity in B16F10 Melanoma Cells.

Lee Y, Hyun C Molecules. 2025; 30(4).

PMID: 40005210 PMC: 11858211. DOI: 10.3390/molecules30040900.


Skin Structure, Physiology, and Pathology in Topical and Transdermal Drug Delivery.

Brito S, Baek M, Bin B Pharmaceutics. 2024; 16(11).

PMID: 39598527 PMC: 11597055. DOI: 10.3390/pharmaceutics16111403.


Effects of SLC45A2 and GPNMB on Melanin Deposition Based on Transcriptome Sequencing in Chicken Feather Follicles.

Li R, Wang Y, Liu Y, Li D, Tian Y, Liu X Animals (Basel). 2023; 13(16).

PMID: 37627399 PMC: 10451703. DOI: 10.3390/ani13162608.


Metatranscriptomics Reveals Sequential Expression of Genes Involved in the Production of Melanogenesis Inhibitors by the Defined Microbial Species in Fermented Unpolished Black Rice.

Sangkaew O, Prombutara P, Roytrakul S, Yompakdee C Microbiol Spectr. 2023; :e0313922.

PMID: 36861996 PMC: 10100879. DOI: 10.1128/spectrum.03139-22.


Miglitol, an Oral Antidiabetic Drug, Downregulates Melanogenesis in B16F10 Melanoma Cells through the PKA, MAPK, and GSK3β/β-Catenin Signaling Pathways.

Kim H, Hyun C Molecules. 2023; 28(1).

PMID: 36615308 PMC: 9822252. DOI: 10.3390/molecules28010115.


References
1.
Kvam E, Tyrrell R . The role of melanin in the induction of oxidative DNA base damage by ultraviolet A irradiation of DNA or melanoma cells. J Invest Dermatol. 1999; 113(2):209-13. DOI: 10.1046/j.1523-1747.1999.00653.x. View

2.
Branza-Nichita N, Negroiu G, Petrescu A, Garman E, Platt F, Wormald M . Mutations at critical N-glycosylation sites reduce tyrosinase activity by altering folding and quality control. J Biol Chem. 2000; 275(11):8169-75. DOI: 10.1074/jbc.275.11.8169. View

3.
Slominski A, Wortsman J, Luger T, Paus R, Solomon S . Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000; 80(3):979-1020. DOI: 10.1152/physrev.2000.80.3.979. View

4.
Slominski A, Wortsman J . Neuroendocrinology of the skin. Endocr Rev. 2000; 21(5):457-87. DOI: 10.1210/edrv.21.5.0410. View

5.
Ujvari A, Aron R, Eisenhaure T, Cheng E, Parag H, Smicun Y . Translation rate of human tyrosinase determines its N-linked glycosylation level. J Biol Chem. 2000; 276(8):5924-31. DOI: 10.1074/jbc.M009203200. View